PTHS compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

PTHSPelthos Therapeutics Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

PTHSPelthos Therapeutics Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PTHS

Reportimpliedrealized× implied

Q2 FY26—▲+0.14%—

May 14 '26—▲+6.46%—

Q1 FY26—▼−4.62%—

Nov 13 '25—▼−7.27%—

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

= impliedPTHS realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

Feb 4 '26

±3.7%

▲+8.15%

×2.22

Q3 FY25±3.7%▲+7.81%×2.11

PTHSPelthos Therapeutics Inc.

9.81▼−40.68%· post 9.82

Mkt cap$36.0MRevenue$16MQ2 FY26Revenue—

AMGNAmgen Inc

466.31▲+1.21%· post 466.40

ClosedOct 30 '26

Mkt cap$251.9BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

Compare

ClosedOct 30 '26

PTHSPelthos Therapeutics Inc.

AMGNAmgen Inc

9.81▼−40.68%post 9.82

Price

466.31▲+1.21%post 466.40

$36.0M

Mkt cap

$251.9B

Q2 FY26$16M

Revenue

$10.1BQ2 FY26

—

Revenue

$36.8BFY25

PTHS9.81▼−40.68%vsAMGN466.31▲+1.21%ClosedOct 30 '26